TY - JOUR
T1 - Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates
AU - Li, Jie
AU - Ulitzky, Laura
AU - Silberstein, Erica
AU - Taylor, Deborah R.
AU - Viscidi, Raphael
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.
AB - Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.
UR - http://www.scopus.com/inward/record.url?scp=84876109796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876109796&partnerID=8YFLogxK
U2 - 10.1089/vim.2012.0076
DO - 10.1089/vim.2012.0076
M3 - Article
C2 - 23573979
AN - SCOPUS:84876109796
SN - 0882-8245
VL - 26
SP - 126
EP - 132
JO - Viral Immunology
JF - Viral Immunology
IS - 2
ER -